Chinese companies remain active buyers of overseas healthcare related assets. Privately owned conglomerate Sanpower Group has agreed to acquire Valeant's biopharma unit Dendreon for US$819.9 million, as Valeant aims to offload its non-core assets, the companies announced.
Earlier today, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Santa Monica, California-based Kite Pharma announced they will establish a joint venture to develop and commercialize cancer treatment in China.
Dendreon's first and only commercialized product is Provenge, an autologous cellular immunotherapy for prostate cancer treatment approved by the U.S. Food and Drug Administration in April 2010.
The number of prostate cance...
This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network